在2022年全国首次"正畸联盟集采"中，正畸材料最高降幅达88%——随着国内集采政策的推进，正畸行 业收费更透明化、规范化，为"牙齿经济"注入了新动能。不过，"以量换价"的集采在改变行业逻辑的同 时，也带来新的挑战。行业会否迎来洗牌，成为业界关注的其中一个焦点话题。 新华财经上海7月15日电（记者杜康）正畸作为一种特殊的医疗产品，兼具医疗属性和一定的消费属 性。第三方数据显示，亚太地区的正畸市场正处于快速增长阶段。这得益于居民可支配收入增加，也得 益于技术的创新。隐形矫治器和数字化口扫技术的普及，极大提升了治疗的舒适性和美观性，在青少年 之外，吸引了更多成年人群进入正畸市场。 因此，如何帮助提升正畸效率、缩短患者治疗周期，是奥美科锚定的创新关键。 "目前，奥美科可为患者提供固定托槽矫治、定制化固定托槽矫治与数字化隐形牙套矫治三大正畸解决 方案。我们的固定托槽产品经历数代创新更迭，不断提升矫治效率，同时还能通过固定托槽与数字化隐 形牙套联合矫治的创新方案，帮助患者缩短治疗周期。"徐晓东介绍，奥美科目前在全球固定正畸产品 线和隐形产品线均有较高市占率。60多年的正畸创新历史，综合的技术优势，给了企业更多创新的可 ...

结合丰富临床病例，沈刚教授详细展示了正雅S8颌位重建装置在各类突面畸形中的应用实践。S8-SGTB 主要用于生理性下颌后退病例，如"颌位性"、"混合I型"、"混合II型"等功能性突面；而S8-SGHB则聚焦 于关节源性错He，适用于突吸退(由于两侧髁突对称性病理吸收而导致下颌后退，简称突吸退)、突吸偏 (由于其两侧髁突呈不对称吸收而导致下颌偏斜，常发生于骨源性及混Ⅱ型突面畸形)、凹增偏(因协调牙 弓宽度，下颌在早期开始偏向一侧，导致一侧髁突呈过度增生、另一侧呈相对抑制，简称凹增偏)等复 杂病因。两者均通过强制性前导实现下颌位置调整，但在临床路径上各有侧重。 针对成年患者"三深错He"的治疗难点，沈刚教授表示：尽管外科手术在部分病例中具有临床必要性，但 多数患者对手术存在抵触心理，而上颌后牙远移与拔牙治疗也常因适应症限制难以实施。为此，他提出 分阶段治疗策略——第一阶段采用带有后牙区He垫的隐形矫治器S8-SGTB进行下颌前导，通过压低下 前牙与下颌后牙同步伸长，实现牙齿移动与下颌前导的协同推进，同时促进髁突后方适应性骨沉积。 此次JAO的重点报道不仅是对沈刚个人成果的认可，更印证了中国隐形正畸科研体系在国际学 ...

Core Viewpoint - Orthodontics involves adjusting the position of teeth and jawbones for better alignment and coordination, with early treatment necessary for conditions affecting craniofacial development [1] Group 1: Conditions Requiring Early Treatment - Clear dental alignment issues such as "crossbite," "overbite," and open bite can affect aesthetics, chewing function, and oral health [2] - Long-term bad oral habits like mouth breathing and thumb sucking can disrupt normal dental and jaw development, leading to misalignment [2] - Early loss of primary teeth or retention of primary teeth can hinder the proper eruption and alignment of permanent teeth [2] - Abnormal jaw development, such as "moon face" or retrognathia, can lead to facial asymmetry, impacting aesthetics and self-confidence [2] Group 2: Choosing the Right Orthodontic Appliance - Removable and functional appliances can guide teeth and jaw development for alignment issues and bad habits [3] - Fixed appliances are necessary for certain alignment problems, using wires and brackets to gradually adjust teeth positions [3] Group 3: Invisible Aligners - Clear aligners gradually move teeth and are aesthetically pleasing, but require patient discipline for consistent wear [4] Group 4: Timing of Orthodontic Treatment - Early treatment is not always better; the optimal timing should be based on the child's specific conditions and growth status [5] - Parents should seek orthodontic consultation and treatment promptly if they notice dental issues in their children [5]

Core Viewpoint - Angelalign is a leading provider of clear aligner treatment solutions in China, maintaining a strong market position and robust revenue growth, with a target price of HK$69.55 per share and a BUY rating initiated [1][3] Group 1: Domestic Market Performance - Angelalign has held the No.1 market share in China's clear aligner market for four consecutive years since 2021, with a 42% market share in 2023 [1] - The company achieved a revenue CAGR of 23.8% from 2019 to 2024, with expectations of an 18.0% CAGR for 2024-27E [1] - Despite macroeconomic headwinds, Angelalign's domestic case volume increased by 3.2% YoY in 2024, supported by expansion into lower-tier cities and the children/adolescents market [1] Group 2: Global Expansion and Profitability - The global clear aligner market is projected to grow from US$6.5 billion in 2024 to US$32 billion by 2030E, representing a CAGR of 30.7% [2] - Angelalign's overseas cases reached 140,700 in 2024, generating US$81 million in revenue, accounting for 30% of total revenue [2] - The company has adopted a "localized operations + M&A" model to establish a global supply chain and local teams, focusing on key markets like Europe and Brazil [2] Group 3: Technological Innovation - Angelalign invests heavily in R&D, maintaining a comprehensive product portfolio and an advanced digital orthodontic platform [3] - The iOrtho platform and digital tools enhance doctor efficiency and loyalty, creating high competitive barriers [3] - The company is expected to achieve a 42.8% overseas revenue CAGR from 2024-27E, while projecting a 3.3% domestic revenue CAGR during the same period [3]